Exane Derivatives’s Sabre SABR Stock Holding History

Exane Derivatives’s Portfolio SABR Stock Details SABR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$14.4K	Hold	2,466	–	–	0.01%	378
2022 Q1	$28.2K	Buy	2,466 +233	+10%	+$2.28K	0.01%	631
2021 Q4	$19.2K	Buy	2,233 +1,548	+226%	+$14.8K	﹤0.01%	576
2021 Q3	$8.11K	Hold	685	–	–	﹤0.01%	713
2021 Q2	$7.97K	Buy	+685	New	+$9.63K	﹤0.01%	753

Other funds holding SABR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

AMH

Apollo Management Holdings New York $8.94B AUM 120.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

CCM

Causeway Capital Management Los Angeles, California $9.24B AUM 21.27% 1-Year Est. Return

PCC

Perry Creek Capital New York $218M AUM 18.4% 1-Year Est. Return

Exane Derivatives's SABR Position: Q2 2022 in Review

Exane Derivatives held its Sabre (SABR) position steady in Q2 2022 at 2,466 shares worth $14.4K. The position accounts for 0.01% of the portfolio, ranked #378.

Exane Derivatives first reported a position in SABR in Q2 2021 and has held it in 5 quarters since. The position peaked at $28.2K in Q1 2022. 325 funds tracked by Wall St. Rank hold SABR as of Q2 2022.

Exane Derivatives held 2,466 shares of Sabre worth $14.4K as of Q2 2022.
Exane Derivatives left its Sabre share count unchanged in Q2 2022.
Sabre made up 0.01% of Exane Derivatives's portfolio in Q2 2022, its #378 holding.
Exane Derivatives first reported a position in Sabre in Q2 2021 and has held it in 5 quarters since.
Exane Derivatives's Sabre position peaked at $28.2K in Q1 2022.
325 funds tracked by Wall St. Rank held Sabre as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.